124 related articles for article (PubMed ID: 22996635)
21. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L
Clin Cancer Res; 2007 Oct; 13(19):5942-51. PubMed ID: 17908991
[TBL] [Abstract][Full Text] [Related]
22. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia.
Vilimas T; Mascarenhas J; Palomero T; Mandal M; Buonamici S; Meng F; Thompson B; Spaulding C; Macaroun S; Alegre ML; Kee BL; Ferrando A; Miele L; Aifantis I
Nat Med; 2007 Jan; 13(1):70-7. PubMed ID: 17173050
[TBL] [Abstract][Full Text] [Related]
23. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K
Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822
[TBL] [Abstract][Full Text] [Related]
24. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
[TBL] [Abstract][Full Text] [Related]
25. [In vitro synergistic effect of bortezomib and pirarubicin on proliferation and apoptosis of T cell lymphoma cell line Hut-78 cells].
Qian ZZ; Wang HQ; Fu K; Ma YL; Hao XS
Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):47-51. PubMed ID: 21429402
[TBL] [Abstract][Full Text] [Related]
26. Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line.
Lü S; Yang J; Chen Z; Gong S; Zhou H; Xu X; Wang J
Exp Hematol; 2009 Jul; 37(7):831-7. PubMed ID: 19426847
[TBL] [Abstract][Full Text] [Related]
27. Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma.
Shapovalov Y; Benavidez D; Zuch D; Eliseev RA
Int J Cancer; 2010 Jul; 127(1):67-76. PubMed ID: 19894220
[TBL] [Abstract][Full Text] [Related]
28. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.
Podar K; Gouill SL; Zhang J; Opferman JT; Zorn E; Tai YT; Hideshima T; Amiot M; Chauhan D; Harousseau JL; Anderson KC
Oncogene; 2008 Jan; 27(6):721-31. PubMed ID: 17653083
[TBL] [Abstract][Full Text] [Related]
29. [The anti-leukemic effects of imatinib, daunorubicin and bortezomib on two leukemia cell lines with Ph(+)].
Yang X; Yang L; Gong YP; Chang H; Zhou RQ; Xing HY; Zheng BH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Sep; 41(5):793-6. PubMed ID: 21302443
[TBL] [Abstract][Full Text] [Related]
30. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
[TBL] [Abstract][Full Text] [Related]
31. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.
Pagnan G; Di Paolo D; Carosio R; Pastorino F; Marimpietri D; Brignole C; Pezzolo A; Loi M; Galietta LJ; Piccardi F; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M
Clin Cancer Res; 2009 Feb; 15(4):1199-209. PubMed ID: 19228726
[TBL] [Abstract][Full Text] [Related]
32. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Roccaro AM; Hideshima T; Raje N; Kumar S; Ishitsuka K; Yasui H; Shiraishi N; Ribatti D; Nico B; Vacca A; Dammacco F; Richardson PG; Anderson KC
Cancer Res; 2006 Jan; 66(1):184-91. PubMed ID: 16397231
[TBL] [Abstract][Full Text] [Related]
33. Augmented efficacy with the combination of blockade of the Notch-1 pathway, bortezomib and romidepsin in a murine MT-1 adult T-cell leukemia model.
Yu P; Petrus MN; Ju W; Zhang M; Conlon KC; Nakagawa M; Maeda M; Bamford RN; Waldmann TA
Leukemia; 2015 Mar; 29(3):556-66. PubMed ID: 25118879
[TBL] [Abstract][Full Text] [Related]
34. Aberrant expression of RasGRP1 cooperates with gain-of-function NOTCH1 mutations in T-cell leukemogenesis.
Oki T; Kitaura J; Watanabe-Okochi N; Nishimura K; Maehara A; Uchida T; Komeno Y; Nakahara F; Harada Y; Sonoki T; Harada H; Kitamura T
Leukemia; 2012 May; 26(5):1038-45. PubMed ID: 22116551
[TBL] [Abstract][Full Text] [Related]
35. A novel Monoclonal Antibody against Notch1 Targets Leukemia-associated Mutant Notch1 and Depletes Therapy Resistant Cancer Stem Cells in Solid Tumors.
Sharma A; Gadkari RA; Ramakanth SV; Padmanabhan K; Madhumathi DS; Devi L; Appaji L; Aster JC; Rangarajan A; Dighe RR
Sci Rep; 2015 Jun; 5():11012. PubMed ID: 26046801
[TBL] [Abstract][Full Text] [Related]
36. Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib.
Mizuno H; Nakayama T; Miyata Y; Saito S; Nishiwaki S; Nakao N; Takeshita K; Naoe T
Leukemia; 2012 Oct; 26(10):2269-76. PubMed ID: 22430634
[TBL] [Abstract][Full Text] [Related]
37. Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells.
Hamamura RS; Ohyashiki JH; Kurashina R; Kobayashi C; Zhang Y; Takaku T; Ohyashiki K
Br J Cancer; 2007 Oct; 97(8):1099-105. PubMed ID: 17895889
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts.
Agnusdei V; Minuzzo S; Frasson C; Grassi A; Axelrod F; Satyal S; Gurney A; Hoey T; Seganfreddo E; Basso G; Valtorta S; Moresco RM; Amadori A; Indraccolo S
Leukemia; 2014 Feb; 28(2):278-88. PubMed ID: 23774673
[TBL] [Abstract][Full Text] [Related]
39. [Effect of bortezomib used alone or in combination with arsenic trioxide on HL-60 cell xenograft in nude mice].
Li L; Meng FY; Fu YB; Cai YX; Sun QX
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Oct; 27(10):1504-6. PubMed ID: 17959525
[TBL] [Abstract][Full Text] [Related]
40. Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.
Yang L; Zhang S; George SK; Teng R; You X; Xu M; Liu H; Sun X; Amin HM; Shi W
Oncotarget; 2015 Jun; 6(17):14953-69. PubMed ID: 25879451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]